Controlling cortisol excess and comorbidities in Cushing’s syndrome with osilodrostat
Maria Fleseriu, John Newell-Price, Mônica R Gadelha, Beverly MK Biller · 2025
Read Controlling cortisol excess and comorbidities in Cushing’s syndrome with osilodrostat by Maria Fleseriu, John Newell-Price, Mônica R Gadelha, Beverly MK Biller (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12719344.txt.
Description
Maria Fleseriu and co-authors review a drug for Cushing's syndrome in a 2025 paper. The disease floods the body with cortisol, driving high blood pressure, diabetes, and a worn-down quality of life.
The drug, osilodrostat, blocks the last step of cortisol making and has cut urine cortisol fast and durably in trials. The authors focus on the largest long-term look at its side benefits, drawn from 210 patients in the LINC 3 and LINC 4 studies. About four in five patients began with high blood pressure and two in five with diabetes. Pressure and blood sugar improved by week twelve and held for over a year, gains that track with better heart health.
Catalog record
| CREATOR | Maria Fleseriu, John Newell-Price, Mônica R Gadelha, Beverly MK Biller |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |